Fundraising Fox
inSoma Bio
YC S20Durham, US · Founded 2018 · Delaware corporation · 4 employees · 8 known investors
Find your way into inSoma Bio
Each arrow is one introduction. Sign up to fill in the first one.
10,552 people can intro you to Ashutosh
Ask Garry Tan to introduce you to Ashutosh Chilkoti
You →Garry · together at YC S20 →Ashutosh
Sign up to find every way you can get introduced to inSoma Bio
- Your email: who you already know at inSoma Bio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the inSoma Bio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.
Founders & leadership· Y Combinator alumni (S20)
inSoma Bio was founded in 2018 by Stefan Roberts and Ashutosh Chilkoti.
AC
Ashutosh ChilkotiChairmanAshutosh Chilkoti is a Biomedical Engineering professor and department chair at Duke University with research focus on genetically encoded biomaterials, drug delivery, and point-of-care diagnostics. He has cofounded five companies including PhaseBio, Sentilus, Gateway Bio, Isolere Bio, and inSoma Bio.
Board
Investors · 8
FemHealth Ventureslisted by FemHealth VenturesShort Hills
How we know: the VCSheet dataset · Not right? Tell us
Y Combinatorlisted by Y CombinatorSan Francisco · $500K
How we know: the Y Combinator directory · Not right? Tell us
360 CapitalreportedMilan · $162K – $10.8M
How we know: Y Combinator's founder network · Not right? Tell us
Asymmetry VenturesreportedRichmond · $125K – $500K
How we know: Y Combinator's founder network · Not right? Tell us
Deep VenturesreportedSan Francisco
How we know: Y Combinator's founder network · Not right? Tell us
MedbluereportedDurham
How we know: Y Combinator's founder network · Not right? Tell us
Oriza HoldingsreportedSuzhou
How we know: Y Combinator's founder network · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$6.9M disclosed across 4 rounds · 2020–2025
▶$2.7MraisedJan 2026 · 15 investors · BiotechnologyRule 506(b)
▶$2.7MraisedJan 2026 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ashutosh ChilkotiExecutive Officer, Director
- Juliana BlumDirector
- Stefan RobertsExecutive Officer, Director
- Heather BrennanDirector
- June S. AlmenoffDirector
- Offering amount
- $4M
- Amount sold
- $2.7M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedMay 2024 · 16 investors · BiotechnologyRule 506(b)
▶$2.7MraisedMay 2024 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- June S. AlmenoffDirector
- Stefan RobertsExecutive Officer, Director
- Juliana BlumDirector
- Ashutosh ChilkotiExecutive Officer, Director
- Heather BrennanDirector
- Offering amount
- $3M
- Amount sold
- $2.7M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedDec 2020 · 31 investors · BiotechnologyRule 506(b)
▶$1.3MraisedDec 2020 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ashutosh ChilkotiExecutive Officer, Director
- Stefan RobertsExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$202KraisedJul 2020 · 7 investors · BiotechnologyRule 506(b)
▶$202KraisedJul 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stefan E. RobertsExecutive Officer, Director
- Ashutosh ChilkotiExecutive Officer, Director
- Offering amount
- $202K
- Amount sold
- $202K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
EnsomaEnsoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment. Its technology aims to selectively and durably modify cells of the hematopoietic system for patients.
Ginkgo BioworksGinkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology. The company serves biopharma, agritech, and industrial biotech companies seeking to engineer organisms at scale.
Sonoma BiotherapeuticsSonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases. The company uses proprietary platform technologies to create targeted and durable Treg cell therapies.
OpentronsOpentrons develops laboratory robots that automate scientific research tasks for scientists and research institutions. The company aims to democratize access to laboratory automation and increase the availability of robotic systems to accelerate discovery in life sciences.
OrsoBioOrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways. The company targets patients with metabolic diseases through precision therapeutic approaches.
SynviviaSynvivia engineers molecules designed to reprogram cells. The company operates in the biotech sector.
ZBioticsZ Biotic develops genetically engineered probiotics designed to improve daily health and wellbeing. The company uses biotechnology to create targeted probiotic products for consumers.
Abalone BioAbalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning. The company uses large-scale biological measurement platforms and AI-powered sequence analysis to discover functional antibody drugs for pharmaceutical and biotechnology applications.
Companies working in the same space as inSoma Bio.
In the news
Frequently asked questions
- What does inSoma Bio do?
- inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.
- Who founded inSoma Bio?
- inSoma Bio was founded by Stefan Roberts, Ashutosh Chilkoti in 2018.
- Who are inSoma Bio's investors?
- inSoma Bio's investors include Duke Capital Partners, FemHealth Ventures, Y Combinator, 360 Capital, Asymmetry Ventures, Deep Ventures, Medblue, Oriza Holdings.
- How much funding has inSoma Bio raised?
- inSoma Bio has disclosed $6.9M raised across 4 rounds.
- Where is inSoma Bio headquartered?
- inSoma Bio is headquartered in Durham, US.